MedTrace Logo

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-12-09

No results posted yet for this study

Summary

Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension

Conditions

  • Sarcoidosis

Interventions

DRUG

Riociguat

Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day

DRUG

Placebo

Placebo given three times a day

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · University of Cincinnati

  • Steve Nathan, MD · Inova Fairfax Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-04-30
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02625558 on ClinicalTrials.gov